M
Michael R. Stratton
Researcher at Wellcome Trust Sanger Institute
Publications - 464
Citations - 162105
Michael R. Stratton is an academic researcher from Wellcome Trust Sanger Institute. The author has contributed to research in topics: Cancer & Mutation. The author has an hindex of 161, co-authored 443 publications receiving 142586 citations. Previous affiliations of Michael R. Stratton include University of Cambridge & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
Peter J. Campbell,Erin Pleasance,Philip J. Stephens,Ed Dicks,Richard Rance,Ian Goodhead,George A. Follows,Anthony R. Green,P. Andy Futreal,Michael R. Stratton +9 more
TL;DR: The potential for ultra-deep resequencing to recapitulate the dynamics of clonal evolution in cancer cell populations is demonstrated and an algorithm to differentiate genuine haplotypes of somatic hypermutations from such artifacts is developed.
Journal ArticleDOI
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Ogechi Ikediobi,Helen Davies,Graham R. Bignell,Sarah Edkins,Claire Stevens,Sarah O’Meara,Thomas Santarius,Tim Avis,Syd Barthorpe,Lisa Brackenbury,Gemma Buck,Adam Butler,Jody Clements,Jennifer Cole,Ed Dicks,Simon A. Forbes,Kristian Gray,Kelly Halliday,Rachel Harrison,Katy Hills,Jonathan Hinton,Christopher I. Hunter,Andy Jenkinson,David T. Jones,Vivienne Kosmidou,Richard Lugg,Andrew Menzies,Tatiana Mironenko,Adrian Parker,Janet Perry,Keiran Raine,David S. Richardson,Rebecca Shepherd,Alex Small,Raffaella Smith,Helen Solomon,Philip J. Stephens,Jon W. Teague,Calli Tofts,Jennifer Varian,Tony Webb,Sofie West,Sara Widaa,Andrew D. Yates,William C. Reinhold,John N. Weinstein,Michael R. Stratton,P. Andrew Futreal,Richard Wooster +48 more
TL;DR: Identification of those cancer genes mutated in the NCI-60, in combination with pharmacologic and molecular profiles of the cells, will allow for more informed interpretation of anticancer agent screening and will enhance the use of the NCi-60 cell lines for molecularly targeted screens.
Journal ArticleDOI
A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy
Christopher I. Hunter,Raffaella Smith,Daniel P. Cahill,Philip J. Stephens,Claire Stevens,Jon W. Teague,Christopher Greenman,Sarah Edkins,Graham R. Bignell,Helen Davies,Sarah O’Meara,Adrian Parker,Tim Avis,Syd Barthorpe,Lisa Brackenbury,Gemma Buck,Adam Butler,Jody Clements,Jennifer Cole,Ed Dicks,Simon A. Forbes,Matthew Gorton,Kristian Gray,Kelly Halliday,Rachel Harrison,Katy Hills,Jonathon Hinton,Andy Jenkinson,David T. Jones,Vivienne Kosmidou,Ross Laman,Richard Lugg,Andrew Menzies,Janet Perry,Robert Petty,Keiran Raine,David S. Richardson,Rebecca Shepherd,Alexandra Small,Helen Solomon,Calli Tofts,Jennifer Varian,Sofie West,Sara Widaa,Andrew D. Yates,Douglas F. Easton,Gregory J. Riggins,Jennifer E. Roy,Kymberly K. Levine,Wolf Mueller,Tracy T. Batchelor,David N. Louis,Michael R. Stratton,P. Andrew Futreal,Richard Wooster +54 more
TL;DR: The evidence suggests that when MSH6 is inactivated in gliomas, alkylating agents convert from induction of tumor cell death to promotion of neoplastic progression, and the potential of large scale sequencing for revealing and elucidating mutagenic processes operative in individual human cancers is highlighted.
Journal ArticleDOI
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
Colin Cooper,Colin Cooper,Rosalind A. Eeles,Rosalind A. Eeles,David C. Wedge,Peter Van Loo,Peter Van Loo,Peter Van Loo,Gunes Gundem,Ludmil B. Alexandrov,Barbara Kremeyer,Adam Butler,Andy G. Lynch,Niedzica Camacho,Charles E. Massie,Jonathan Kay,Hayley J. Luxton,S. Edwards,Zsofia Kote-Jarai,Nening Dennis,Sue Merson,Daniel Leongamornlert,Jorge Zamora,Cathy Corbishley,Sarah Thomas,Serena Nik-Zainal,Manasa Ramakrishna,Sarah O’Meara,Lucy Matthews,Jeremy Clark,Rachel Hurst,Richard Mithen,Robert G. Bristow,Robert G. Bristow,Paul C. Boutros,Paul C. Boutros,Michael Fraser,Michael Fraser,Susanna L. Cooke,Keiran Raine,David T. Jones,Andrew Menzies,Lucy Stebbings,Jon Hinton,Jon W. Teague,Stuart McLaren,Laura Mudie,Claire Hardy,Elizabeth Anderson,Olivia Joseph,Victoria Goody,Ben Robinson,Mark Maddison,Stephen J. Gamble,Christopher Greenman,Daniel M. Berney,Steven Hazell,Naomi Livni,Cyril Fisher,Chris Ogden,Pardeep Kumar,Alan Thompson,C. R. J. Woodhouse,David Nicol,Erik Mayer,Tim Dudderidge,Nimish Shah,Vincent Gnanapragasam,Thierry Voet,Peter J. Campbell,Andrew Futreal,Douglas F. Easton,Anne Y. Warren,Christopher S. Foster,Michael R. Stratton,Hayley C. Whitaker,Ultan McDermott,Daniel Brewer,Daniel Brewer,Daniel Brewer,David E. Neal +80 more
TL;DR: Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of three men, demonstrating the existence of ongoing abnormal mutational processes, consistent with field effects, underlying carcinogenesis.
Journal ArticleDOI
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers
Richard S. Maser,Bhudipa Choudhury,Peter J. Campbell,Bin Feng,Kwok-Kin Wong,Alexei Protopopov,Jennifer O'Neil,Alejandro Gutierrez,Elena Ivanova,Ilana Perna,Eric Lin,Vidya Mani,Shan Jiang,Kate McNamara,Sara Zaghlul,Sarah Edkins,Claire Stevens,Cameron Brennan,Eric S. Martin,Ruprecht Wiedemeyer,Omar Kabbarah,Cristina W. Nogueira,Gavin Histen,Jon C. Aster,Marc R. Mansour,Veronique Duke,Letizia Foroni,Adele K. Fielding,Anthony H. Goldstone,Jacob M. Rowe,Yaoqi A. Wang,A. Thomas Look,Michael R. Stratton,Lynda Chin,P. Andrew Futreal,Ronald A. DePinho +35 more
TL;DR: The results indicate that murine and human tumours experience common biological processes driven by orthologous genetic events in their malignant evolution.